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Deliberate removal of T cell help improves
virus-neutralizing antibody production
Mike Recher1,5, Karl S Lang1,5, Lukas Hunziker1,2,5, Stefan Freigang1, Bruno Eschli1, Nicola L Harris1,
Alexander Navarini1, Beatrice M Senn1, Katja Fink1, Marius Lo¨tscher1, Lars Hangartner1, Raphae¨l Zellweger1,
Martin Hersberger3, Alexandre Theocharides4, Hans Hengartner1 & Rolf M Zinkernagel1
The B cell response to lymphocytic choriomeningitis virus is characterized by a CD4+ T cell–dependent polyclonal
hypergammaglobulinemia and delayed formation of virus-specific neutralizing antibodies. Here we provide evidence that,
paradoxically, because of polyclonal B cell activation, virus-specific T cell help impairs the induction of neutralizing antibody
responses. Experimental reduction in CD4+ T cell help in vivo resulted in potent neutralizing antibody responses without
impairment of CD8+ T cell activity. These unexpected consequences of polyclonal B cell activation may affect vaccine strategies
and the treatment of clinically relevant chronic bacterial, parasitic and viral infections in which hypergammaglobulinemia is
regularly found.
Lymphocytic choriomeningitis virus (LCMV) is a noncytopathic RNA
virus that is initially controlled by a strong CD8 + T cell response in a
perforin-dependent way1,2. In contrast, LCMV-neutralizing antibodies
usually develop late in infection, after day 50, and remain at low titer3.
This phenomenon is also found after infection with other poorly
cytopathic or noncytopathic viruses such as human immunodefi-
ciency virus (HIV)4 and hepatitis C virus5,6. Neutralizing antibodies
directed against low-cytopathic viruses increase in titer when CD8 +
T cell (cytotoxic T lymphocyte (CTL)) function is impaired or
absent3,7,8. Possible mechanisms have been postulated to include
CD8 + T cell–dependent immunopathology9,10, enhanced viral repli-
cation in the absence of CTLs2,8 or the need for affinity or avidity
maturation of specific antibodies. These observations also suggest a
competitive relationship between cellular and humoral antiviral
immune responses, as has been successfully modeled theoretically11.
LCMV infection induces a strong CD4 + T cell–dependent, virus-
nonspecific, polyclonal hypergammaglobulinemia12,13, a phenomenon
often associated with ‘persistence-prone’, low-cytopathic viruses like
HIV and hepatitis C virus or with chronic bacterial and parasitic
infections. Yet a biological function for polyclonal B cell activation has
remained elusive14.
Here we have evaluated the function of T helper cells and found
that paradoxically, because of polyclonal B cell activation, CD4 +
T cells impaired the formation of virus-neutralizing antibodies
and favored virus persistence. This inverse causal relationship
of T cell help and virus-specific antibody formation was modi-
fied only indirectly by CD8 + T cells. Experimental deliberate
suppression of T helper responses after LCMV infection resulted in
enhanced neutralizing antibody formation while leaving CTL
responses intact.
RESULTS
Polyclonal B cell activation versus neutralizing antibodies
Compared with results obtained with control C57BL/6 mice, infection
of CD8 + T cell–depleted C57BL/6 or CD8a-deficient (Cd8a/) mice
with high-dose (2  106 PFU) LCMV, strain WE (LCMV-WE)
resulted in increased titers of neutralizing antibodies (Fig. 1a), corre-
lating with increased viral replication (Fig. 1b). However, virus-
induced polyclonal hypergammaglobulinemia was also modified by
CTL function, as both CD8 + T cell–depleted C57BL/6 mice and
Cd8a/ mice showed reduced polyclonal B cell activation early (day
12) after LCMV infection (Fig. 1c). CD4 + T cells are required for
hypergammaglobulinemia13. Thus, we examined whether CD4 + T cell
function was affected by functional CD8 + T cell depletion. Indeed,
CD4 + T cells from CD8 + T cell–depleted or Cd8a/ mice showed a
significant reduction in interferon-g (IFN-g) production after re-
stimulation with phorbol 12-myristate 13-acetate (PMA) and iono-
mycin, compared with that of CD4 + T cells from C57BL/6 mice
(Fig. 1d). This impaired CD4 + T cell function strictly correlated with
the reduced peak in hypergammaglobulinemia in the absence of
functional CD8 + T cells (Fig. 1c), although restimulation by PMA
and ionomycin also induces some IFN-g production in naive mice,
and absolute virus-specific CD4 + T cell activation may therefore
be slightly overestimated. Thus, early polyclonal B cell activation
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correlated with CD4 + T cell function but was inversely correlated with
neutralizing antibody responses.
Impairment of neutralizing antibody responses by CD4+ T cells
To analyze whether the stated inverse relationship was due to a direct
suppressive effect of virus-specific T cell help on neutralizing antibody
formation, we infected mice with LCMV-WE in the presence or
absence of adoptively transferred LCMV-specific CD4 + T helper
cells. We obtained these CD4 + cells from Smarta1 mice, which
carry a transgenic T cell receptor specific for the LCMV T helper
epitope consisting of glycoprotein amino acids 61–80 (GP(61–80))15.
We examined Cd8a/ mice as recipients to exclude the possibility of
a direct effect of T helper cells on CTL function. LCMV-infected
Cd8a/ mice that did not receive Smarta1 splenocytes developed a
strong neutralizing antibody response (Fig. 2a and ref. 7). This result
correlated with a transient reduction (499%) in blood virus titers
(Fig. 2b and ref. 7). In contrast, Cd8a/ mice that received cells from
Smarta1 mice failed to mount measurable neutralizing activity
(Fig. 2a), and blood virus titers remained consistently high
(Fig. 2b). This indicated that the addition of virus-specific CD4 +
T cell help inhibited the production of neutralizing antibodies. As
expected, hypergammaglobulinemia was increased in the presence of
additional virus-specific T cell help (Fig. 2c).
Next, we examined if the reduction in virus-specific T cell help was
followed by enhanced neutralizing antibody formation. These experi-
ments profited from knowledge of two characterized immunodomi-
nant LCMV-derived major histocompatibility complex (MHC) class II
epitopes, the aforementioned GP(61–80) and nucleoprotein-derived
NP(309–327)16,17, which account for most of the LCMV-specific
CD4 + T cell response18. We took advantage of a newly isolated
LCMV variant, LCMV-WEdel (ref. 19), which contains an eight–
amino acid deletion at positions 61–68 of the LCMV glycoprotein,
spanning the immunodominant MHC class II H-2b epitope GP(61–
80) (ref. 16,17; Table 1). This epitope is recognized by Smarta1 T
helper cells. Infection of Cd8a/ mice with LCMV-WEdel induced an
early and strong neutralizing antibody response (Fig. 2a). This
response was not altered by the presence of CD4 + T cells from
Smarta1 mice (Fig. 2a). This indicated that the inhibition of the
neutralizing antibody response by virus-specific CD4 + T cells
occurred in an epitope-specific way. Consistent with the early induc-
tion of neutralizing antibodies, Cd8a/ mice infected with LCMV-
WEdel showed rapid clearance of virus from peripheral blood (Fig. 2b)
and had only moderate hypergammaglobulinemia (Supplementary
Fig. 1 online). These experiments demonstrated a causal, inverse
correlation of CD4 + T cell–dependent polyclonal B cell activation
and neutralizing antibody responses. In addition, virus dosage influ-
enced the degree of functional CD4 + T cell anergy in the absence of
CTLs. Infection of Cd8a/ mice with low virus doses (for example,
200 PFU LCMV-WE) was followed by robust IFN-g production by
virus-specific CD4 + T cells, whereas high virus doses (2  106 PFU
LCMV-WE) led to impaired CD4 + T cell function (Supplementary
Fig. 1 online). Accordingly, polyclonal B cell activation was suppressed
and neutralizing antibodies were high after high-dose LCMV-WE
infection, whereas hypergammaglobulinemia was enhanced and neu-
tralizing antibody titers were low after low-dose LCMV-WE infection
(Supplementary Fig. 1 online). Low-dose (200 PFU) LCMV-WEdel
induced only minimal polyclonal B cell activation in Cd8a/ mice.
Again, the decreased hypergammaglobulinemia found after LCMV-
WEdel infection correlated inversely with neutralizing antibody
production (Supplementary Fig. 1 online).
Antibody formation in CD8+ T cell–competent mice
Our data have provided evidence that virus-specific CD4 + T cells may
directly negatively influence neutralizing antibody formation. In
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Table 1 Sequence of the LCMV glycoprotein CD4+ T cell epitope
Amino acid position 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
WE Tyr Gly Leu Asn Gly Pro Asp Ile Tyr Lys Gly Val Tyr Gln Phe Lys Ser Val Glu Phe Asp
WEdel Tyr – – – – – – – – Lys Gly Val Tyr Gln Phe Lys Ser Val Glu Phe Asp
–, deleted amino acid.
Figure 1 Influence of CD8+ T cells on B cell and
CD4+ T cell responses. (a–c) C57BL/6 mice that
were depleted in vivo of CD8 T cells on days –3
and –1 (Anti-CD8) or were left untreated (Control)
and Cd8a/ mice (Cd8a/) were infected
with 2  106 PFU LCMV-WE on day 0 (times,
horizontal axes). (a) Quantification of LCMV-WE-
specific neutralizing antibodies. (b) Virus plaque
assay of virus titers in blood. (c) Analysis of total
serum immunoglobulins by serum electrophoresis.
(d) Splenocytes from Cd8a/ mice or from
CD8+ T cell–depleted C57BL/6 mice (monoclonal
antibody YTS 169.4) were infected with 2  106
PFU LCMV-WE. Then, 12 d later, cells were
restimulated in vitro with PMA and ionomycin for
6 h and IFN-g production by CD4+ T cells was
quantified by intracellular cytokine staining and
flow cytometry. Splenocytes from naive mice
served as a control. Data are expressed as
mean 7 s.e.m. of four to six mice per group and
are representative of two to three experiments.
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contrast, CD8 + T cells seemed to suppress antibody responses
indirectly by reducing viral load and thereby maintaining T helper
cell function. Thus, we postulated that experimentally reduced but not
completely absent CD4 + T cell help should impair hypergammaglo-
bulinemia and promote the production of neutralizing antibodies
in CTL-competent mice. For this, we infected wild-type C57BL/6
mice with LCMV-WEdel,. To confirm that the immunodominant
GP(61–80) epitope was absent in vivo after infection with the variant
virus, we infected C57BL/6 mice with 200 PFU LCMV-WEdel or wild-
type LCMV-WE. Splenocytes infected with wild-type but not variant
LCMV demonstrated strong peptide-specific CD4 + T cell IFN-g
production after in vitro restimulation 8 d later (Fig. 3a). In contrast,
restimulation of the same splenocytes with the NP(309–327) MHC
class II peptide produced comparable IFN-g production (Fig. 3a). To
determine the function of subdominant epitopes, we infected C57BL/6
mice with 200 PFU LCMV-WE or 200 PFU LCMV-WEdel and re-
stimulated splenocytes polyclonally with PMA and ionomycin. We
detected approximately half the percentage of IFN-g producing CD4 +
T cells in mice infected with LCMV-WEdel compared with that in mice
infected with LCMV-WE (Fig. 3a). Thus, the loss of the immuno-
dominant MHC class II epitope resulted in weakened CD4 + T
cell responses.
To further confirm that LCMV-WEdel had a complete absence of
the GP(61–80) epitope in vivo, we infected Smarta1 mice with 200
PFU LCMV-WE or LCMV-WEdel. Whereas infection with LCMV-WE
induced a notable downregulation of the activation marker CD62L on
Smarta1 CD4 + T cells at day 5 after infection, we found no indication
of Smarta1 T cell activation after infection with LCMV-WEdel
(Fig. 3b). As noted for CD8 + T cell–deficient mice, low-dose infection
(200 PFU) of wild-type C57BL/6 mice with LCMV-WEdel resulted in
enhanced neutralizing antibody titers compared with LCMV-WE
infection. Neutralizing serum activity became detectable by day 30
and remained increased until at least day 200 (Fig. 3c), whereas
neutralizing antibodies remained low after LCMV-WE infection. Sera
from LCMV-WEdel-infected mice neutralized both LCMV-WEdel and
wild-type LCMV-WE virus in vitro, whereas sera from LCMV-WE-
infected mice could not neutralize either virus. These data indicated
that the glycoprotein structure was conserved in both viruses and was
equally accessible to neutralizing antibodies (Fig. 3c). This conclusion
was supported by the comparable neutralization of LCMV-WEdel and
LCMV-WE in vitro by the monoclonal LCMV-WE-neutralizing anti-
body KL25 (ref. 20; Fig. 3d). LCMV glycoprotein–specific enzyme-
linked immunosorbent assay (ELISA) IgG antibodies were also
enhanced after infection with LCMV-WEdel compared with antibodies
present after infection with LCMV-WE (Fig. 3e). These ELISA IgG
titers were induced early after infection (days 12–20), in contrast to
neutralizing antibodies, which appeared after days 30–40 (Fig. 3c). In
contrast, early total serum immunoglobulin concentrations (which
represent mainly IgG isotypes13) were decreased in LCMV-WEdel-
infected mice compared with LCMV-WE-infected mice (Fig. 3f).
These results indicated that an intermediate amount of CD4 + T cell
help reduced polyclonal B cell activation and was associated with
increased virus-specific IgG formation.
To rule out the possibility that a dominant function of the LCMV-
WEdel glycoprotein was itself responsible for enhanced neutralizing
antibody responses, we co-infected C57BL/6 mice with 200 PFU
LCMV-WEdel and LCMV-WE. After co-infection, virus-specific IgG
production was very low (Fig. 3e) and was associated with an
enhanced hypergammaglobulinemia compared with that after infec-
tion with LCMV-WEdel alone (Fig. 3f). This result suggested that
infection with LCMV-WEdel did not mediate an increased production
of virus-specific antibodies itself, but that this increase was a result of
the reduced polyclonal B cell activation. We next examined whether
the different titers of LCMV-neutralizing antibodies found after
infection with LCMV-WE or LCMV-WEdel resulted in different
protective capacities against a challenge infection. We collected and
pooled sera from mice given primary infection with 200 PFU LCMV-
WE or LCMV-WEdel (days 40-80 after infection) and transferred this
sera into naive C57BL/6 mice, which we then challenged intravenously
with 200 PFU LCMV-WE. We also used control C57BL/6 mice that
did not receive serum and infected them with LCMV-WE. On day 4
after challenge infection, virus titers in spleens in mice that had
received serum from LCMV-WEdel-infected mice were 0.1% those of
mice that received the same volume of serum from LCMV-WE-
infected mice (Fig. 3g). Transfer of serum from LCMV-WE mice
mediated only minor protection compared with that of control mice
that had not received LCMV-immune serum (Fig. 3g).
Effects of partial CD4+ T cell depletion
The hypothesis that CD4 + T cell help may inhibit the formation of
virus-neutralizing antibodies through the promotion of polyclonal
B cell activation ‘predicts’ that experimental reduction but not
complete elimination of functional T cell help should result in
enhanced virus-specific antibody titers after wild-type LCMV-WE
infection. We treated mice with titrated doses of the CD4 + T cell–
depleting monoclonal antibody YTS191.6 (ref. 21) before infecting the
mice with 200 PFU LCMV-WE on day 0. The normal protocol
of CD4 + T cell depletion with two injections of YTS191.6, on days
3 and 1, resulted in complete disappearance of CD4 + T cells from
the blood up to day 12, as assessed by flow cytometry (Fig. 4a),
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Figure 2 Inverse correlation between virus-specific T cell help and neutralizing antibody responses in Cd8a/ mice. Cd8a/ mice were infected with
5  103 PFU LCMV-WE (WE) or LCMV-WEdel (WEdel). The mice also received 1  107 Smarta1 splenocytes intravenously on the day of infection
( + Smarta1) or were left untreated (times, horizontal axes). (a) Analysis of sera by neutralization assay against LCMV-WE. (b) Virus plaque assay of blood
viral titers. (c) Analysis of total serum immunoglobulins by serum electrophoresis. Five individual mice were tested on day 12 after infection. Pooled serum
of two to three mice was analyzed at days 20 and 30. Data are expressed as mean 7 s.e.m. of three to five mice per group except in b, for which data from
three individual mice are presented. All data are representative of two separate experiments (total n ¼ 5–8).
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associated with an absence of serum hypergammaglobulinemia
(Fig. 3f). In contrast, treatment with a 1:100 dilution of the depleting
antibody had a transient effect, such that CD4 + T cells were initially
depleted but had already regained normal numbers by day 12 after
infection (Fig. 4a). Such transient and partial CD4 + T cell depletion
led to the development of increased LCMV-specific IgG antibody titers
(Fig. 4b). As expected, complete depletion of CD4 + T cells resulted in
a failure to produce LCMV-specific IgG antibodies (Fig. 4b).
The positive effect of partial CD4 + T cell depletion on the
production of neutralizing antibodies was similarly demonstrated
in CD8 + T cell–deficient mice, which had already cleared the
LCMV-WE infection from the peripheral blood by day 20 (Fig.
4c,d). Thus, the partial depletion of CD4 + T cells provided another
line of evidence supporting the proposal that limited T cell help
results in the formation of an accelerated and improved neutralizing
antibody response.
Coexistence of neutralizing antibody and CTL responses
Early CD4 + T cell help is important in the generation of CD8 + T cell
memory21–23. Whereas the initial clonal burst and early CD8 + T cell
function is mostly CD4 + T cell independent, memory CD8 + T cell
responses apparently require CD4 + T cell help. Thus, the potential
therapeutic use of virus variants lacking immunodominant MHC class
II epitopes or partial CD4 + T cell depletion in vivo may become a
‘double-edged sword’. That is, enhanced neutralizing antibodies would
have to compensate for a potentially impaired CTL memory response.
We therefore examined acute and memory CTL responses induced by
infection with LCMV-WE (with or without partial CD4 + T cell
depletion) or LCMV-WEdel. At early time points after infection (day
8), we found no significant differences in either LCMV-specific
tetramer–positive CD8 + T cell numbers (data not shown) or IFN-g
production after short-term (6 h) in vitro re-stimulation with
MHC class I peptides derived from LCMV glycoprotein (GP(33–41)
or GP(276–284)) or LCMV nucleoprotein (NP(396–404); Fig. 5a).
Numbers of tetramer-positive memory CD8 + T cells from mice
infected with LCMV-WE (with or without partial CD4 + T cell
depletion) or LCMV-WEdel were also comparable at day 120
after infection (Fig. 5b,c). To test the functional capacity of these
CD8 + T cells, we partially depleted C57BL/6 mice of T helper
cells and challenged these and nondepleted control mice, 130 days
after infection with 200 PFU LCMV-WE, with CFSE-labeled
splenocytes pulsed with the LCMV GP(33–41) peptide. We used
flow cytometry to analyze the elimination of injected cells.
Within 4 h, mice subjected to partial CD4 + T cell depletion had
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Figure 3 Infection with LCMV-WEdel results in moderate hypergammaglobulinemia but potent neutralizing antibody responses in immunocompetent
C57BL/6 mice. (a) C57BL/6 mice were infected with 200 PFU LCMV-WE (WE) or LCMV-WEdel (WEdel) or were left uninfected (Naive). At 8 d after
infection, splenocytes were re-stimulated with the immunodominant LCMV GP(61–80) or LCMV NP(309–327), or with PMA and ionomycin. IFN-g
production gated on CD4+ T cells was assessed by flow cytometry. (b) Smarta1 mice were infected with 200 PFU LCMV-WE or LCMV-WEdel or were left
uninfected. At 5 d after infection, activation of gated CD4+ T cells was assessed by flow cytometry of CD62L expression. (c) C57BL/6 mice were infected
with 200 PFU LCMV-WE or LCMV-WEdel, then sera were tested against LCMV-WE (-WE) or against LCMV-WEdel (-WEdel) by neutralization assay (times,
horizontal axis). (d) The LCMV-neutralizing monoclonal antibody KL25 was serially diluted twofold (starting at 1 mg/ml) in a plaque-neutralization assay
with LCMV-WE or LCMV-WEdel; samples were analyzed in triplicate. (e,f) C57BL/6 mice were infected with 200 PFU LCMV-WE or LCMV-WEdel. C57BL/6
mice depleted of CD4+ T cells with monoclonal antibody YTS191.6 (anti-CD4) and C57BL/6 mice co-infected with 200 PFU LCMV-WE and LCMV-WEdel
(WE + WEdel) served as controls. (e) ELISA of binding of serum IgG to recombinant LCMV glycoprotein. (f) Analysis of total serum immunoglobulin
concentrations by serum electrophoresis. Data in a–f represent mean 7 s.e.m. of four to eight individual mice and are representative of at least two
separate experiments. (g) Pooled serum (100 ml) obtained 50–80 d after infection of C57BL/6 mice with 200 PFU LCMV-WE (WE serum) or LCMV-WEdel
(WEdel serum) was injected intravenously into naive C57BL/6 hosts. Then, 2 h later, recipient mice were challenged with 200 PFU LCMV-WE and
4 d later, virus titers in the spleen were assessed by plaque assay. Control, infection of C57BL/6 mice without serum transfer. Data points represent
results from individual mice.
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eliminated 65.6% 7 4.97% of the peptide-pulsed cells, whereas
LCMV-WE-infected control C57BL/6 mice showed a slightly reduced
cytotoxicity in vivo (38.9% 7 2.54%; Fig. 5d). These experiments
indicated that potent neutralizing antibody and CD8 + T cell
responses could potentially coexist in vivo and that partial depletion
of CD4 + T cells did not obviously impair CTL memory responses in
our test conditions.
Influence of virus replication on antibody responses
The idea that T helper cell–dependent polyclonal B cell activation can
impair production of virus-neutralizing antibodies was supported by
experiments in both immunocompetent and CD8 + T cell–deficient
mice. Nevertheless, neutralizing antibody responses were usually
shifted toward higher titers in experiments in which CD8 + T
cells were absent. This suggested an additional function for virus
replication in the formation of neutralizing antibody responses. To
directly determine this influence, we examined mice deficient for
type I and type II interferon receptors (AGR mice), in which virus
replication is enhanced24–27.
Low-dose (200 PFU) LCMV-WE infection of AGR mice resulted in
the development of an ‘LCMV carrier status’. We did not detect
neutralizing antibodies in AGR mice infected with LCMV-WE
(Fig. 6a), despite the presence of high-titer virus replication
(Fig. 6b). In contrast, infection of AGR-mice with 200 PFU LCMV-
WEdel resulted in sera that were able to neutralize sera even when
diluted 1,000-fold. This neutralizing antibody response occurred in
the presence of viral antigen concentrations that were comparable to
those seen after wild-type LCMV-WE infection (Fig. 6b, days 8–20).
However, by day 25 after infection, the appearance of neutralizing
antibodies in mice infected with LCMV-WEdel coincided with
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Figure 5 Normal early and memory CTL function can coexist with enhanced neutralizing antibody responses in immunocompetent C57BL/6 mice.
(a) C57BL/6 mice were infected with 200 PFU LCMV-WE or LCMV-WEdel. Then, 8 d later splenocytes were re-stimulated in vitro for 6 h with the LCMV-
derived immunodominant MHC class I peptides (GP(33–41) (gp33); GP(276–284) (gp276); NP(396–404) (np496)) and IFN-g production by CD8+ T cells
was assessed by flow cytometry. Data are presented as mean 7 s.e.m. of five individual mice per group and have been repeated twice with similar results.
(b) C57BL/6 mice were infected with 200 PFU LCMV-WE (WE); some were partially depleted of CD4+ T cell depleted on day 1 before infection on day 0
(WE + partial depletion). Then, 120 d later, LCMV-specific CD8+ T cells numbers were determined by LCMV gp33– and LCMV np396–specific tetramer
binding and flow cytometry. (c) C57BL/6 mice were infected with 200 PFU LCMV-WE or LCMV-WEdel. Then, 150 d later, LCMV-specific CD8
+ T cells
numbers were measured by LCMV gp33– and LCMV np396–specific tetramer staining and flow cytometry. (d) In vivo cytotoxic capacity of memory CD8+
T cells from C57BL/6 mice partially depleted of CD4+ T cells or from nondepleted C57BL/6 mice, 130 d after infection, determined by challenge with
CFSEhi LCMV gp33 peptide–labeled splenocytes. Data in b–d represent mean 7 s.e.m. of four to five individual mice per group and are representative
of one experiment.
Figure 4 Enhanced neutralizing antibody
response after partial CD4+ T cell depletion in
vivo in both immunocompetent C57BL/6 and
Cd8a/ mice. C57BL/6 mice (a,b) and Cd8a/
mice (c,d) were infected with 200 PFU LCMV-WE
(times, horizontal axes). Before infection, mice
were depleted of CD4+ T cells, completely
(Complete depletion) or partially (Partial
depletion), with titrated amounts of monoclonal
antibody YTS191.6. Control, normal C57BL/6
mice (a,b) or normal Cd8a/ mice (c,d) without
depletion. (a) Degree of CD4+ T cell depletion,
monitored by flow cytometry. (b) ELISA of LCMV
glycoprotein–specific IgG antibodies. (c) Plaque
assay of virus titers in blood. (d) Neutralization
assay of LCMV-WE-neutralizing antibodies.
Data represent mean 7 s.e.m. of four to five
individual mice and are representative of two
independent experiments.
938 VOLUME 5 NUMBER 9 SEPTEMBER 2004 NATURE IMMUNOLOGY
A R T I C L E S
©
20
04
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 
ht
tp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
ei
m
m
u
n
o
lo
gy
viral clearance to below the limit of detection in blood. As noted for
CD8 + T cell–deficient mice, neutralizing antibody ‘escape variants’
eventually arose and could be detected in the blood at late time
points (4day 80; Fig. 6b).
LCMV-WE infection of AGR mice resulted in a sharp increase in
total serum immunoglobulin concentrations (Fig. 6c), detectable by
day 10 after infection and occurring in parallel with a massive
downregulation of the activation marker CD62L on blood CD4 + T
cells (Fig. 6d). In contrast, only moderate hypergammaglobulinemia
was measured in AGR mice infected with LCMV-WEdel (Fig. 6c),
associated with reduced CD4 + T cell activation (Fig. 6d). Thus, here
the induction of the neutralizing antibody response occurred inde-
pendently of high viral load (apparent in mice lacking interferon
receptors), but yet again correlated with reduced CD4 + T cell–
dependent early hypergammaglobulinemia. These experiments also
indicated that a combination of high virus replication and limited
early polyclonal B cell activation resulted in enhanced neutralizing
antibody responses.
Virus-specific and nonspecific B cell competition
To elucidate the mechanisms by which CD4 + T cell–dependent
hypergammaglobulinemia impaired production of LCMV-specific
neutralizing antibodies, we investigated whether this effect was limited
to LCMV antigens or whether antibody responses to LCMV-unrelated
antigens were also affected30 (Fig. 7). We examined whether LCMV-
induced polyclonal B cell activation correlated with decreased neutra-
lizing antibody responses against vesicular stomatitis virus (VSV) after
co-infection with both viruses. We infected C57BL/6 mice with 2 106
PFU VSV 6 d after LCMV-WE infection and determined the forma-
tion of neutralizing antibodies to VSV. We used this infection schedule
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Figure 6 The efficiency of the neutralizing
antibody response can be predicted largely by
the extent of polyclonal B cell activation but is
also modified by the extent of virus replication.
(a–c) AGR mice were infected with 200 PFU
LCMV-WE (filled symbols) or LCMV-WEdel (open
symbols). Times, horizontal axes. (a) Virus
neutralization assay of neutralizing antibody titers
to LCMV-WE (-WE) and LCMV-WEdel (-WEdel).
(b) Plaque-forming assay of blood virus titers.
(c) Analysis of total serum immunoglobulins
by serum electrophoresis. Data represent
mean 7 s.e.m. of two to five individual mice per
time point. All data (a–c) are representative of
two separate experiments. (d) Flow cytometry
of CD62L expression on peripheral blood CD4+
lymphocytes 7 d after infection with 200 PFU
LCMV-WE (dotted line) or LCMV-WEdel (solid
line). Data are of one representative mouse per
group (total, n ¼ 5–6).
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Figure 7 LCMV-induced polyclonal B cell competition acts in an antigen-nonspecific way and is dependent on B cell precursor frequency. (a–c) Cd8a/
mice (VSV, LCMV (Cd8a/)) or C57BL/6 mice (either depleted of CD8+ T cells with monoclonal antibody YTS 169.4 on days 3 and 1 (VSV, LCMV (anti-
CD8) or left untreated (VSV, LCMV)), were infected with 2  106 PFU LCMV-WE on day 0. Uninfected C57BL/6 mice served as controls (VSV). On day 6
after LCMV infection, mice were superinfected with 2  106 PFU VSV. Times, horizontal axes. (a,b) VSV-neutralization assay of VSV-neutralizing IgG
(a) and total VSV-neutralizing immunoglobulins (IgM plus IgG; b). (c) Analysis of total serum immunglobulins by serum electrophoresis. (d) VSV-specific B
cell receptor–transgenic VI10Yen splenocytes28 (Vl10Yen; 1  107, 1  105 or 1  103 cells) were adoptively transferred intravenously into naive
C57BL/6 mice on day 1 before LCMV-WE-infection (2  106 PFU) on day 0 and VSV-neutralizing IgG-responses were measured after VSV infection
(2  106 PFU) on day 6 with a VSV-neutralization assay (time, horizontal axis). (e) C57BL/6 mice were infected intravenously with 2  106 PFU
LCMV-WE (LCMV, DNP-albumin) or were left uninfected (DNP-albumin). Then, 6 d later, 100 mg DNP-albumin was injected intravenously. Sera were tested
by ELISA to detect of binding of IgG to DNP-albumin (time, horizontal axis). Data represent mean 7 s.e.m. of three to six mice per time point. All data are
representative of two separate experiments. Downward arrows (a,e) indicate time of immunization.
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so that the peak of LCMV-induced hypergammaglobulinemia (day 12)
would coincide with the time of IgG isotype switching in response to
VSV infection (day 6). In C57BL/6 mice preinfected with LCMV-WE,
we noted a reduction in neutralizing IgG antibodies to VSV (anti-VSV
IgG) compared with that of control mice infected with VSV alone
(Fig. 7a). This effect was also apparent in CD8 + T cell–depleted or
Cd8a/ mice (Fig. 7a), indicating that LCMV-induced CD8 + T
cell–mediated immunopathology was not (or was not solely) respon-
sible for the effect on neutralizing antibody responses noted. Although
polyclonal B cell activation was reduced in CD8 + T cell–deficient
mice (Fig. 7c), it was obviously sufficient to suppress VSV-specific
IgG production (Fig. 7a). In contrast, early neutralizing IgM anti-
bodies to VSV were increased in mice co-infected with LCMV and
VSV (Fig. 7b). Thus, LCMV-induced polyclonal B cell activation
(Fig. 7c) was also able to inhibit IgG isotype switching of B cells
‘encoding’ antibodies specific for VSV. We next examined whether
the LCMV-induced polyclonal B cell competition could be compen-
sated by the presence of increased VSV-specific B cell precursor
frequencies. We adoptively transferred splenocytes from a transgenic
mouse expressing a ‘switchable’ neutralizing anti-VSV B cell receptor,
VI10Yen28, into naive C57BL/6 mice. We then infected recipient
mice with 2 106 PFU LCMV-WE and coinfected the mice 6 d
later with 2 106 PFU VSV, as described above. Inhibition of
neutralizing anti-VSV IgG by LCMV coinfection was reversed by
increased numbers of VI10Yen B cells in a dose-dependent way
(Fig. 7d). This indicated that the inhibition was effective only at
low B cell precursor frequencies. To confirm this finding with
another experimental approach, we analyzed the ability of LCMV-
induced polyclonal B cell activation to ‘compete out’ IgG responses
specific for (2,4-dinitrophenyl)-albumin (DNP-albumin). High B cell
precursor frequencies exist against DNP-albumin hapten carrier
conjugates in naive C57BL/6 mice29. Anti-DNP-albumin IgG titers
were not impaired but were even increased by LCMV preinfection,
reflecting the polyclonal B cell stimulation (Fig. 7e). Thus, we
noted the competitive effect of LCMV-induced polyclonal B cell
activation against LCMV-related and LCMV-unrelated specificities,
however, only if precursor frequencies of the relevant B cells were
relatively low.
DISCUSSION
Delayed neutralizing antibody responses after infection with a persis-
tent virus was, in our experiments, directly correlated with the
activation kinetics and functional responsiveness of virus-specific
CD4 + T cells. A reduction in CD4 + T cell function and/or reduction
in CD4 + T cell numbers reduced polyclonal B cell stimulation,
apparently by ‘concentration’ of specific T cell help onto virus-specific
B cells. In contrast, strong (and even normal) virus-specific CD4 + T
cell activation resulted in heightened early polyclonal B cell activation,
which competed with virus-specific B cell activation and the forma-
tion of neutralizing antibodies. An absence of CD8 + T cells indirectly
affected neutralizing antibody production by enhancing virus replica-
tion, which in turn favored CD4 + T cell anergy or unresponsiveness.
The inverse correlation between early hypergammaglobulinemia
and neutralizing antibody responses affected also LCMV-unrelated
protective antibody responses (for example, against VSV). This
competition for antigen-specific B cells was seen only for B cells
with physiologically low precursor frequencies.
Our experiments here cannot determine whether this biological
consequences of polyclonal B cell activation results from a competition
for B cell survival factors or for ‘anatomical niches’ that promote
B cell isotype switching by rendering cognate CD4 + T cell–B cell
interactions more or less efficient. Should the competition involve
anatomical structures, then CD8 + T cell–induced immunopathologi-
cal disruption of lymphoid tissue organization may further enhance
this effect9,10. Additionally, increased virus replication may influence
the kinetics of avidity and/or affinity maturation of virus-specific
antibodies. The evidence presented here suggests that the latter
effects are additional or secondary to the influence of polyclonal
B cell activation.
Whereas high-affinity neutralizing antibodies are key effector
mechanisms against acutely cytopathic virus infections, such as rabies
(or VSV) and poliovirus31, infections with poorly cytopathic or
noncytopathic viruses, including LCMV, hepatitis C virus or HIV,
typically result in delayed formation of protective neutralizing anti-
bodies3,31,32. Instead, in these latter infections, virus replication is
initially controlled by strong, although often transient, CD8 + T cell
responses33. For persistent virus-host interactions, a competitive
coexistence of humoral and cellular immunity has been described
experimentally8 and theoretically11; thus, neutralizing antibodies may
act as an additional line of defense when CD8 + T cell responses
become weakened. This competitive coexistence may be beneficial to
the host by averting a combination of strong cytotoxicity and antibody
responses that may favor immunopathology and autoimmune mani-
festations. However, virus persistence after HIV or LCMV infection
could be substantially reduced if both CTLs and neutralizing anti-
bodies were experimentally available at early time points after infec-
tion by exogenous addition34,35. In addition, the combination of
neutralizing antibodies and CD8 + T cells should suppress the risk
of either CTL or neutralizing antibody escape variant formation7,36.
We believe that coevolution of such noncytopathic or low cytopathic
viruses and mammalian hosts has yielded mechanisms that avoid
production of potent neutralizing antibody responses, thereby favor-
ing virus persistence. With overwhelming virus infections such as
LCMV, virus may persist not only as a result of CD8 + T cell deletion
and/or exhaustion but also as a consequence of increased polyclonal B
cell activation37.
Given the demonstration that CD8 + T cells impair the formation of
neutralizing antibodies partially indirectly by induction of CD4 +
T cell anergy, it might be difficult but not impossible to induce
both a protective CTL and an accelerated neutralizing antibody
response. In fact, we have demonstrated here that a reduction in
CD4 + T cell function early during LCMV infection can decrease
polyclonal B cell activation and thus can improve neutralizing anti-
body responses in immunocompetent hosts while leaving CTL
responses intact.
What may be learned from the LCMV model infections presented
here to better elucidate of HIV pathogenesis? High HIV viremia can be
associated with an anergic state of virus-specific CD4 + T cells38.
Antiviral therapy reduces HIV-induced polyclonal hypergamma-
globulinemia39 and in parallel increases neutralizing antibody
responses against autologous virus40. These results are all consistent
with our findings with LCMV. In addition, early hyperactivity of
CD4 + T cells represents an independent risk factor for disease
progression after HIV infection41. As for LCMV, a delay in neutralizing
antibody responses associated with accentuated T helper cell responses
might enhance HIV replication and promote exhaustion or deletion or
aging of protective T cells. HIV-induced hypergammaglobulinemia
inversely correlates with HIV-unrelated IgG titers induced by vaccina-
tion against measles or diphteria42, reminiscent of the LCMV-VSV
B cell competition described here. Other factors may additionally
account for the delayed appearance of HIV-neutralizing antibodies,
including depletion of CD4 + T cells, qualitative differences in CD4 +
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T cell function, disruption of lymphatic architecture or glycan shields
that conceal the neutralizing epitope on the HIV glycoprotein43,44.
Our experiments may suggest potential strategies for experimentally
and therapeutically influencing persistent virus infections by reducing
virus-induced polyclonal B cell activation and thereby enhancing
neutralizing antibody production. The deliberate impairment of
T cell help during immunization either by the use of vaccines
with mutated or deleted CD4 + T cell epitopes or, alternatively,
by partial depletion of CD4 + T cell function in vivo, although
counterintuitive and probably difficult to control, may be worth
careful consideration.
METHODS
Mice. All mice were bred and maintained in specific pathogen–free conditions
and experiments were done in accordance with institutional and Swiss guide-
lines. Cd8a/, VI10Yen and Smarta1 mice were all on a C57BL/6 (H-2b)
background. AG129 mice were on a 129/Sv (H-2b) background. All mice were
obtained from the Institute for Labortierkunde, Faculty of Veterinary Medicine,
University Zu¨rich-Irchel, Switzerland.
Virus. The LCMV strain WE was originally obtained from F. Lehmann-Grube
(Heinrich Pette Institute, Hamburg, Germany) and was propagated on L929
and/or MC57 cells. Mice were infected intravenously with 2 102 PFU
(low dose), 5 103 PFU (intermediate dose) or 2 106 PFU (high dose)
LCMV-WE. LCMV-WEdel was previously isolated from LCMV-WE-infected
DBA/2 mice19. VSV-Indiana (VSV-IND) and VSV-New Jersey (VSV-NJ) were
originally obtained from D.Kolakofsky (University of Geneva, Switzerland) and
were grown on BHK cells. Mice were infected intravenously.
Sequencing. The cDNA encoding LCMV-WEdel glycoprotein was sequenced
as described19.
Detection of virus and neutralizing antibody titers. LCMV virus titers
were determined by plaque-forming assay on MC57 fibroblasts as
described45. Detection of neutralizing activity against LCMV in mouse sera
has been described45. Neutralizing activity against LCMV-WE or LCMV-WEdel
was measured by plaque-reduction assay. The neutralizing titer was defined
as the log2 dilution resulting in half-maximal reduction of plaques compared
with the same amount of virus incubated with control sera from uninfected
mice or medium alone. A titer of less than 1 indicates no detectable
neutralization of a 1:10 predilution of serum incubated with an equal volume
of virus for 90 min before addition of the mixture to MC57 fibroblasts.
Neutralizing total (IgM plus IgG) and IgG antibodies to VSV were measured
as described46.
In vivo depletion of CD4 + and CD8 + T cells. Depletion of cells used rat
monoclonal antibodies specific for CD4 (YTS 191.6) or CD8 (YTS 169.4) as
described20 and were provided by H. Waldmann (Therapeutic Immunology
Group, Oxford, UK). Antibody (200 ml) was injected intraperitoneally on days
3 and 1 (before infection at day 0). For partial CD4 + T cell depletion,
200 ml of a 1:100 dilution (in PBS) was injected intraperitoneally on day 1.
The efficiency of depletion was confirmed by flow cytometry of peripheral
blood cells with fluorescein isothiocyanate– or phycoerythrin-labeled anti-CD4
or anti-CD8 (BD Pharmingen).
Serum protein electrophoresis to quantify hypergammaglobulinemia. Detec-
tion of serum immunoglobulin as a function of total serum protein was done
by the Department of Clinical Chemistry, University Hospital, Zu¨rich, Switzer-
land. Serum was separated by agarose gel electrophoresis (Sebia) and the
fractions were quantified with a densitometer (Beckmann Coulter).
LCMV-specific tetramers. Tetramers specific for LCMV glycoprotein
(GP(33–41) and GP(276–284)) and nucleoprotein (NP(396–404)) have been
described47. Phycoerythrin-labeled tetramers were used.
Intracellular cytokine staining for IFN-c and flow cytometry. Splenocytes
were re-stimulated overnight with baculovirus-derived recombinant LCMV
nucleoprotein in RPMI medium supplemented with FCS (10% final concen-
tration) and b-mercaptoethanol (0.1 mM final concentration). For T cell re-
stimulation, cells were cultured for 6 h in medium containing phorbol
12-myristate 13-acetate (PMA; 50 ng/ml) and ionomycin (500 ng/ml) or
alternatively one of the following peptides (at a concentration of 50 mg/ml):
GP(61–80), GP(33–41) and GP(276–286) or NP(309–328) and NP(396–404).
Brefeldin A (10 mg/ml; Sigma-Aldrich) was added for the last 5 h of culture.
Cells were then collected, washed once in PBS with 4% FCS and 12.5 mM
EDTA and stained with phycoerythrin-conjugated anti-CD4 or anti-CD8 (BD
Pharmingen). After being washed, cells were fixed with 4% paraformaldehyde
(in PBS) for 10 min, then were permeabilized with PBS containing 4% FCS,
12.5 mM EDTA and 0.1% saponin (Sigma-Aldrich). For intracellular cytokine
staining, cells were incubated for 45 min at 4 1C with fluorescein isothiocya-
nate– or allophycocyanin-conjugated anti-IFN-g (BD PharMingen). After
being washed twice with permeabilization buffer, cells were resuspended in
PBS containing 4% FCS and 12.5 mM EDTA and were analyzed with a
FACScan or FACSCalibur (BD).
Examination of CD4 + T cell activation. Expression of the selectin CD62L on
blood CD4 + T cells was examined by staining with anti-mouse
CD4–fluorescein isothiocyanate and anti-mouse CD62L–phycoerythrin (both
from BD Pharmingen), followed by analysis with a FACSCalibur (BD).
In vivo cytotoxicity. Assays for in vivo cytotoxicity were done with C57BL/6
splenocytes incubated for 1 h with or without LCMV-derived MHC class I
GP(33–41) peptide and labeled for 10 min with carboxyfluorescein diacetate
succinimidyl diester (CFSE) at a concentration of 5 mg/ml (CFSEhi, peptide-
labeled splenocytes) or 0.5 mg/ml (CFSElo, splenocytes not labeled with peptide;
Molecular Probes). ‘LCMV memory’ or naive control mice were injected
intravenously with 1  107 cells of each fraction. The number of CFSE + cells
remaining in the blood after 4 h was determined by flow cytometry. Specific
cytotoxicity was calculated with the following equation: cytotoxicity (%) ¼ 1 –
[(CFSEhi (memory)/CFSElo (memory))/(CFSEhi (naive)/CFSElo (naive))].
ELISA. For analysis of LCMV glycoprotein, 96-well plates were coated with
100 ml recombinant LCMV glycoprotein supernatant derived from HEK293
cells transfected with LCMV glycoprotein vector. Sera prediluted 1:30 were
incubated for 90 min, washed with PBS containing 0.5% Tween 20, then
incubated further with anti-mouse IgG–horseradish peroxidase (1:1,000 dilu-
tion; Sigma-Aldrich) for detection of virus-specific IgG responses. For the
detection of IgG antibodies specific for DNP-albumin conjugate, plates were
coated overnight with 10 mg/ml of DNP–serum albumin (Sigma-Aldrich).
Plates were then blocked for 2 h at 25 1C with 2% BSA in PBS. Sera prediluted
1:30 were incubated for 90 min. Anti-mouse IgG–horseradish peroxidase
(1:1,000 dilution; Sigma-Aldrich) was used to detect specific IgG responses.
In all ELISAs, a green color reaction was produced with 2,2¢-azino-bis
(3-ethylbenzothiazoline-6-sulfonate) as a substrate (ABTS; Boehringer-Man-
nheim). The ELISA titer was defined as the log2 serum dilution resulting in an
optical density at 450 nm twofold above background.
KL25 plaque-neutralization assay. For these assays, 30–50 PFU LCMV-WE or
LCMV-WEdel were incubated in 96-well plates for 90 min with twofold
dilutions (starting at 0.5 mg/ml) of the LCMV-neutralizing monoclonal anti-
body KL25 (ref. 20). Plaques were then evaluated on MC57 fibroblasts as
described45. Foci were counted in triplicate and the percentage of plaque
formation in the absence of KL25 (considered 100% PFU) was calculated and
plotted against (log2) KL25 dilution.
Serum transfer. For measurement of the protective antibody capacity against
a challenge LCMV infection, 100 ml of pooled serum after LCMV-WE or
LCMV-WEdel infection of C57BL/6 mice (40–80 d after infection) was
adoptively transferred intravenously into naive C57BL/6 mice. The mice were
challenged 2 h later with 200 PFU LCMV-WE and spleen virus titers were
measured 4 d later by plaque assay.
Statistical analysis. Data are expressed as mean and s.e.m. Where indicated,
significance was assessed with the paired t-test. P values above 0.05 were
considered not significant.
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Note: Supplementary information is available on the Nature Immunology website.
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